Company intelligence / Profile preview

Intracel

Frederick, Maryland, United Statesintracel.co.uk ↗

Ownership: Public · ITCI
Development stage: Commercial

Overview

Intracel developed OncoVAX, a patient-specific autologous colon cancer vaccine. The company received FDA Special Protocol Assessment for a confirmatory pivotal Phase III study of OncoVAX in colon cancer as of July 2006. There is no evidence the company or its programs have advanced since then, and it appears to be inactive[7].

Therapeutic areas: Oncology
Modalities: VaccineImmunotherapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

Intracel KLH

Unknown

Financials

Market cap: $14B
Total revenue: $199.2M
Enterprise value: $13.1B

Beyond the preview

Go deeper on Intracel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intracel.

Explore the full profile